Role of basal inflammatory status as a predictor of survival in bevacizumab-treated advanced non-small cell lung cancer (NSCLC) patients

Autor:	Vito Barbieri, P. Correale, Pierfrancesco Tassone, Antonella Licchetta, C. Botta, P. Blardi, Annamaria Guglielmo, Giovanni Mantovani, G. Chiriaco, Serena Apollinari, Pierosandro Tagliaferri, Elena Bestoso
Rok vydání:	2011
Předmět:	Oncology Cancer Research medicine.medical_specialty Bevacizumab business.industry medicine.drug_class non-small cell lung cancer (NSCLC) medicine.disease Monoclonal antibody Basal (phylogenetics) Internal medicine Toxicity medicine Lung cancer business medicine.drug
Zdroj:	Journal of Clinical Oncology. 29:7582-7582
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.15_suppl.7582
Popis:	7582 Background: At present, there is a great concern for the toxicity and costs associated with anti-VEGF Bevacizumab (Bv) mAb use in lung cancer treatment, underscoring the need of biomarkers pre...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::0a34d9b743a5907b1ff4a59ac429d7d2 https://doi.org/10.1200/jco.2011.29.15_suppl.7582 Zobrazit plný text záznamu